India's Suven Pharma jumps as govt greenlights $1.15 billion FDI deal

19-09-2023Comments (0)Print

06-03-2023

28-10-2021

11-06-2021

26-03-2020

16-10-2023

11-10-2023

09-10-2023

Shares of Hyderabad, India-headquartered Suven Pharmaceuticals (BOM: 543064) hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda.

The approval by the Cabinet Committee on Economic Affairs (CCEA) relates to the acquisition of up to 76.1% of the company and will fund the capacity expansion of the Indian pharma company.…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.

BerhyandaCompanies, mergers and acquisitionsCyprusFocus OnGenericsGovernment AffairsIndiaSuven PharmaceuticalsVC & Investment